F-theory from fundamental five-branes Linch, William D.; Siegel, Warren
The journal of high energy physics,
02/2021, Letnik:
2021, Številka:
2
Journal Article
Recenzirano
Odprti dostop
A
bstract
We describe the worldvolume for the bosonic sector of the lower-dimensional F-theory that embeds 4D, N=1 M-theory and the 3D Type II superstring. The worldvolume (5-brane) theory is that of ...a single 6D gauge 2-form
X
MN
(
σ
P
) whose field strength is selfdual. Thus unlike string theory, the spacetime indices are tied to the worldsheet ones: in the Hamiltonian formalism, the spacetime coordinates are a
10
of the GL(5) of the 5
σ
’s (neglecting
τ
). The current algebra gives a rederivation of the F-bracket. The background-independent subalgebra of the Virasoro algebra gives the usual section condition, while a new type of section condition follows from Gauß’s law, tying the worldvolume to spacetime: solving just the old condition yields M-theory, while solving only the new one gives the manifestly T-dual version of the string, and the combination produces the usual string. We also find a covariant form of the condition that dimensionally reduces the string coordinates.
F-theory with worldvolume sectioning Linch, William D.; Siegel, Warren
The journal of high energy physics,
04/2021, Letnik:
2021, Številka:
4
Journal Article
Recenzirano
Odprti dostop
A
bstract
We describe the worldvolume for the bosonic sector of the lower-dimensional F-theory that embeds 5D, N=1 M-theory and the 4D type II superstring. This theory is a complexification of the ...fundamental 5-brane theory that embeds the 4D, N=1 M-theory of the 3D type II string in a sense that we make explicit at the level of the Lagrangian and Hamiltonian formulations. We find three types of section condition: in spacetime, on the worldvolume, and one tying them together. The 5-brane theory is recovered from the new theory by a double dimensional reduction.
F-theory superspace Linch, William D.; Siegel, Warren
The journal of high energy physics,
03/2021, Letnik:
2021, Številka:
3
Journal Article
Recenzirano
Odprti dostop
A
bstract
We consider, at the linearized level, the superspace formulation of lower-dimensional F-theory. In particular, we describe the embedding of 3D Type II super-gravity of the superstring, or ...4D,
N
= 1 supergravity of M-theory, into the corresponding F-theory in full detail, giving the linearized action and gauge transformations in terms of the prepotential. This manifestly supersymmetric formulation reveals some features not evident from a component treatment, such as Weyl and local S-supersymmetry invariances. The linearized multiplet appears as a super 3-form (just as that for the manifestly T-dual theory is a super 2-form), reflecting the embedding of M-theory (as the T-dual theory embeds Type II supergravity). We also give the embedding of matter multiplets into this superspace, and derive the F-constraint from the gauge invariance of the gauge invariance.
In the CORAL study, 255 chemosensitive relapses with diffuse large B-cell lymphoma (DLBCL) were consolidated with autologous stem cell transplantation (ASCT), and 75 of them relapsed thereafter. The ...median time between ASCT and progression was 7.1 months. The median age was 56.1 years; tertiary International Prognosis Index (tIPI) observed at relapse was 0-2 in 71.6% of the patients and >2 in 28.4%. The overall response rate to third-line chemotherapy was 44%. The median overall survival (OS) was 10.0 months (median follow-up: 32.8 months). Thirteen patients received an allogeneic SCT, and three a second ASCT. The median OS was shorter among patients who relapsed <6 months (5.7 months) compared with those relapsing ⩾12 months after ASCT (12.6 months, P=0.0221). The median OS in patients achieving CR, PR or no response after the third-line regimen was 37.7 (P<0.0001), 10.0 (P=0.03) and 6.3 months, respectively. The median OS varied according to tIPI: 0-2: 12.6 months and >2: 5.3 months (P=0.0007). In multivariate analysis, tIPI >2, achievement of response and remission lasting <6 months predicted the OS. This report identifies the prognostic factors for DLBCL relapsing after ASCT and thus helps to select patients for experimental therapy.
A
bstract
We derive the component structure of 11D,
N
= 1/8 supergravity linearized around eleven-dimensional Minkowski space. This theory represents 4 local supersymmetries closing onto 4 of the 11 ...spacetime translations without the use of equations of motion. It may be interpreted as adding 201 auxiliary bosons and 56 auxiliary fermions to the physical supergravity multiplet for a total of 376 + 376 components. These components and their transformations are organized into representations of SL(2;
C
)
× G
2
.
Several different mutations collaborate with the fusion proteins in core-binding factor acute myeloid leukemia (CBF-AML) to induce leukemogenesis, but their prognostic significance remains unclear. ...We screened 354 predominantly younger (<60 years) adults with t(8;21) (n=199) or inv(16) (n=155) entered into UK MRC trials for KIT, FLT3 tyrosine kinase domain (FLT3(TKD)), N-RAS, K-RAS and c-CBL mutations and FLT3 internal tandem duplications (FLT3(ITD)) and assessed the impact of relative mutant level on outcome. Overall, 28% had KIT, 6% FLT3(ITD), 10% FLT3(TKD), 27% RAS and 6% CBL mutations. Mutant levels for all genes/loci were highly variable. KIT mutations were associated with a higher cumulative incidence of relapse but in multivariate analysis this was only significant for cases with a higher mutant level of 25% or greater (95% confidence interval (CI)=1.01-1.52, P=0.04). Similarly, only FLT3(ITD-HIGH) was a significant adverse factor for overall survival (OS; CI=1.27-5.39, P=0.004). Conversely, FLT3(TKD-HIGH) and CBL(HIGH) were both favorable factors for OS (CI= 0.31-0.89, P=0.01 and CI=0.05-0.85, P=0.02, respectively). KIT mutations were frequently lost at relapse, which is relevant to minimal residual disease detection and the clinical use of KIT inhibitors. These results indicate that relative mutant level should be taken into account when evaluating the impact of mutations in CBF-AML.
A
bstract
We propose a superspace formulation of
conformal supergravity in six dimensions. The corresponding superspace constraints are invariant under super-Weyl transformations generated by a real ...scalar parameter. The known variant Weyl super-multiplet is recovered by coupling the geometry to a super-3-form tensor multiplet. Isotwistor variables are introduced and used to define projective superfields. We formulate a locally supersymmetric and super-Weyl invariant action principle in projective superspace. Some families of dynamical supergravity-matter systems are presented.
Salvage chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard second-line treatment for relapsed and refractory diffuse large B-cell lymphoma (DLBCL). However, the ...strategy is less clear in patients who require third-line treatment. Updated outcomes of 203 patients who could not proceed to scheduled ASCT in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL) are herein reviewed. In the intent-to-treat analysis, overall response rate to third-line chemotherapy was 39%, with 27% CR or CR unconfirmed, and 12% PR. Among the 203 patients, 64 (31.5%) were eventually transplanted (ASCT 56, allogeneic SCT 8). Median overall survival (OS) of the entire population was 4.4 months. OS was significantly improved in patients with lower tertiary International Prognostic Index (IPI), patients responding to third-line treatment and patients transplanted with a 1-year OS of 41.6% compared with 16.3% for the not transplanted (P<0.0001). In multivariate analysis, IPI at relapse (hazard ratio (HR) 2.409) and transplantation (HR 0.375) independently predicted OS. Third-line salvage chemotherapy can lead to response followed by transplantation and long-term survival in DLBCL patients. However, improvement of salvage efficacy is an urgent need with new drugs.
Outcomes for patients with high-risk diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP chemotherapy are suboptimal but, to date, no alternative regimen has been shown to improve survival ...rates. This phase 2 trial aimed to assess the efficacy of a Burkitt-like approach for high-risk DLBCL using the dose-intense R-CODOX-M/R-IVAC regimen.
Eligible patients were aged 18–65 years with stage II–IV untreated DLBCL and an International Prognostic Index (IPI) score of 3–5. Patients received alternating cycles of CODOX-M (cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate) alternating with IVAC chemotherapy (ifosfamide, etoposide and high-dose cytarabine) plus eight doses of rituximab. Response was assessed by computed tomography after completing all four cycles of chemotherapy. The primary end point was 2-year progression-free survival (PFS).
A total of 111 eligible patients were registered; median age was 50 years, IPI score was 3 (60.4%) or 4/5 (39.6%), 54% had a performance status ≥2 and 9% had central nervous system involvement. A total of 85 patients (76.6%) completed all four cycles of chemotherapy. There were five treatment-related deaths (4.3%), all in patients with performance status of 3 and aged >50 years. Two-year PFS for the whole cohort was 67.9% 90% confidence interval (CI) 59.9–74.6 and 2-year overall survival was 76.0% (90% CI 68.5–82.0). The ability to tolerate and complete treatment was lower in patients with performance status ≥2 who were aged >50 years, where 2-year PFS was 43.5% (90% CI 27.9–58.0).
This trial demonstrates that R-CODOX-M/R-IVAC is a feasible and effective regimen for the treatment of younger and/or fit patients with high-risk DLBCL. These encouraging survival rates demonstrate that this regimen warrants further investigation against standard of care.
ClinicalTrials.gov (NCT00974792) and EudraCT (2005-003479-19).
•R-CODOX-M/R-IVAC is an effective regimen for treatment of high-risk DLBCL and high-grade B-cell lymphoma (IPI score 3–5).•Treatment was well tolerated in patients aged <50 years, or aged 50–65 with performance status 0 or 1.•The 2-year PFS was 67.9% (90% CI: 59.9–74.6) for the whole cohort.•This regimen warrants further evaluation against standard of care in high-risk DLBCL.
PDF
